Viva Las Vegas!

Good Call Media travelled to Las Vegas, USA for the 2024 Western Veterinary Conference (WVC).

The Conference is one of the largest events of its kind in the world and our joint owners, Fiona Molloy and Nik Wood were to be seen filming a whole series of interviews on the Conference floor as part of our ongoing high profile in the veterinary sector.

We were based on Volition Veterinary’s stand as their Nu.Q® Vet Cancer Test continues in its expansion across the USA into Europe and Asia. Earlier this year Volition announced the expansion of the availability of the test throughout North America, through the IDEXX Laboratories, Inc. (“IDEXX”) reference laboratory network in the U.S.

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “IDEXX is a global leader in pet healthcare innovation and well-positioned to roll out the IDEXX Nu.Q® Canine Cancer Screen worldwide. It is a simple, cost effective, easy to use blood test for screening older or ‘at risk’ dogs.

“Our Nucleosomics™ technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer and improve the health and wellbeing of pets and pet owners.

“IDEXX’s launch of the Nu.Q® Canine Cancer Screen in the U.S. this week, under our previously announced supply agreement¹, ultimately provides worldwide customer reach through its global reference laboratory network as we continue to commercialize our transformational Nu.Q® technology within the companion animal healthcare sector, and capitalize on the significant opportunities available.”

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q® technology go to: